Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 7;9(8):e70196.
doi: 10.1002/hem3.70196. eCollection 2025 Aug.

Working towards harmonization of clinical trial reporting in Hodgkin lymphoma

Carsten Kobe  1 , Philippe Armand  2 , Sven Borchmann  3 , Graham P Collins  4 , Anne-Segolene Cottereau  5 , Justin Ferdinandus  3 , Alex F Herrera  6 , Davide Rossi  7   8   9 , Wouter J Plattel  10 , Sally F Barrington  11 , Martin Hutchings  12
Affiliations

Working towards harmonization of clinical trial reporting in Hodgkin lymphoma

Carsten Kobe et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

J.F. reports honoraria from Takeda Oncology. A.‐S.C. has received travel support from Roche. P.A. reports consultancy: Merck, BMS/Celgene, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome, Regeneron, Epizyme, AstraZeneca, Genentech/Roche, Xencor, Foresight, and ATB Therapeutics; research funding: Kite; research funding (institutional): Merck, BMS‐Celgene, Affimed, Adaptive, Tensha, Otsuka, Sigma Tau, Genentech/Roche, IGM, and AstraZeneca; honoraria: Merck and BMS. W.J.P. has received speaker fees and/or travel support from Johnson&Johnson, Pfizer, and Takeda Oncology. A.F.H. reports research funding: Bristol Myers Squibb, Genentech, Merck, AstraZeneca, and Pfizer; consultancy: Bristol Myers Squibb, Genentech, Merck, AstraZeneca, Takeda, Genmab, Pfizer, AbbVie, and Allogene Therapeutics. M.H. reports consultant/advisor: AbbVie, AstraZeneca, Genmab, Johnson&Johnson, Merck, Roche, and Takeda; research support (institution): AbbVie, Arvinas, AstraZeneca, Bristol Myers‐Squibb, Celgene, Genentech, Genmab, Incyte, Johnson&Johnson, Merck, Novartis, Pfizer, Roche, and Takeda. All others have nothing to disclose.

References

    1. Kanoun S, Berriolo‐Riedinger A, Cottereau AS, et al. Total metabolic tumor volume and tumor dissemination are independent prognostic factors in advanced Hodgkin lymphoma. Blood. 2021;138(suppl 1):880. 10.1182/blood-2021-147177 - DOI
    1. Cottereau AS, Versari A, Loft A, et al. Prognostic value of baseline metabolic tumor volume in early‐stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood. 2018;131(13):1456‐1463. 10.1182/blood-2017-07-795476 - DOI - PubMed
    1. Driessen J, Kersten MJ, Visser L, et al. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP. Leukemia. 2022;36(12):2853‐2862. 10.1038/s41375-022-01717-8 - DOI - PubMed
    1. Plattel WJ, van den Berg A, Visser L, et al. Plasma thymus and activation‐regulated chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica. 2012;97(3):410‐415. 10.3324/haematol.2011.053199 - DOI - PMC - PubMed
    1. Plattel WJ, Visser L, Diepstra A, et al. Interim thymus and activation regulated chemokine versus interim (18)F‐fluorodeoxyglucose positron‐emission tomography in classical Hodgkin lymphoma response evaluation. Br J Haematol. 2020;190(1):40‐44. 10.1111/bjh.16514 - DOI - PMC - PubMed

LinkOut - more resources